Oncology

The biosimilar to Rituxan is expected to erode market share of the mainstay cancer drug for Roche.

After positive Phase 3 trial results, Karyopharm Therapeutics expects FDA to clear Xpovio.

FDA cleared the first generic sodium iodide product to treat hyperthyroidism and carcinoma of the thyroid.

FDA is evaluating risks to patients.

FDA approved yet another indication for pembrolizumab (Keytruda) to treat patients with recurrent, locally advanced or metastatic, squamous cell carcinoma of the esophagus (ESCC).

A record number of new oncology treatments launched in the US last year and spending on cancer drugs soared. Here are the top 6 cancer drug trends revealed in the report.

FDA approves cabozantinib to treat patients with hepatocellular carcinoma, a community in need of new therapeutic options.

 A new non-small cell lung cancer (NSCLC) treatment is available to healthcare providers immediately.  

Here are the top 2 novel cancer drugs cleared by the agency.

Here are the top 3 new approvals from FDA.

FDA’s approval of an expanded indication for a prostate cancer drug could net 2 pharmaceutical manufacturers billions of dollars.

Pharma makers are voluntarily recalling several drugs containing this active ingredient, used to treat high blood pressure and heart failure, since they may contain a carcinogen.

A pharma maker is under fire for raising prices on its cancer drugs. Meanwhile, there were two major cancer drug approvals in June. Here are the top 3 cancer news articles in the past month.

A combination melanoma treatment that was just approved by FDA is available through select specialty pharmacies.

The manufacturer of bevacizumab (Avastin), snagged FDA approval for yet another type of cancer.

FDA approved the first biosimilar to Neulasta, as well as a new combination treatment for osteoarthritis pain and hypertension and a new drug to treat chronic lymphocytic leukemia.

The manufacturer of two cancer drugs hiked the price on the medicines despite President Donald Trump’s new plan to lower drug prices.

FDA expanded the indication on cabozantinib (Cabometyx, Exelixis) to treat patients with advanced renal cell carcinoma (RCC).